The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:2838-2840 June 26, 2008 Number 26
NextNext

Hypereosinophilic Syndrome and Mepolizumab

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Rothenberg, M. E.
-PubMed Citation
To the Editor: Rothenberg and colleagues (March 20 issue)1 provide data on the use of mepolizumab, an anti–interleukin-5 monoclonal antibody, for corticosteroid sparing in patients with non–life-threatening hypereosinophilic syndrome who were negative for FIP1L1–PDGFRA. Although the corticosteroid dose and the eosinophil count were significantly lowered in patients in the mepolizumab group, as compared with those in the placebo group, the safety of corticosteroid tapering with mepolizumab was not clearly demonstrated. For example, in the mepolizumab group, dyspnea and asthma occurred in 16% and 5% of patients, respectively, and one patient died from cardiac arrest. Since cardiac involvement and pulmonary . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.